NCT04661384View on ClinicalTrials.gov

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

November 17, 2025

Study Completion Date

November 17, 2025

Conditions
EpendymomaGlioblastomaMedulloblastomaRecurrent Metastatic Malignant Neoplasm in the Leptomeninges
Interventions
BIOLOGICAL

IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes

Given ICV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER